14. Inhibition of Proliferation of Vascular Smooth Muscle Cells by Heparin

Author(s):  
William Ε. Benitz
2009 ◽  
Vol 23 (7) ◽  
pp. 1284-1291 ◽  
Author(s):  
Beobyi Lee ◽  
Eo-Jin Lee ◽  
Dong-Il Kim ◽  
Sung-kyu Park ◽  
Wun-Jae Kim ◽  
...  

2009 ◽  
Vol 296 (4) ◽  
pp. C828-C839 ◽  
Author(s):  
Domenick A. Prosdocimo ◽  
Dezmond C. Douglas ◽  
Andrea M. Romani ◽  
W. Charles O'Neill ◽  
George R. Dubyak

Extracellular inorganic pyrophosphate (PPi) is a potent suppressor of physiological calcification in bone and pathological calcification in blood vessels. Ectonucleotide pyrophosphatase/phosphodiesterases (eNPPs) generate PPi via the hydrolysis of ATP released into extracellular compartments by poorly understood mechanisms. Here we report that cultured vascular smooth muscle cells (VSMC) from rat aorta generate extracellular PPi via an autocrine mechanism that involves ATP release tightly coupled to eNPP activity. The nucleotide analog β,γ-methylene ATP (MeATP or AMPPCP) was used to selectively suppress ATP metabolism by eNPPs but not the CD39-type ecto-ATPases. In the absence of MeATP, VSMC generated extracellular PPi to accumulate ≥600 nM within 2 h while steadily maintaining extracellular ATP at 1 nM. Conversely, the presence of MeATP completely suppressed PPi accumulation while increasing ATP accumulation. Probenecid, which inhibits PPi efflux dependent on ANK, a putative PPi transporter or transport regulator, reduced extracellular PPi accumulation by approximately twofold. This indicates that autocrine ATP release coupled to eNPP activity comprises ≥50% of the extracellular PPi-generating capacity of VSMC. The accumulation of extracellular PPi and ATP was markedly attenuated by reduced temperature but was insensitive to brefeldin A, which suppresses constitutive exocytosis of Golgi-derived secretory vesicles. The magnitude of extracellular PPi accumulation in VSMC cultures increased with time postplating, suggesting that ATP release coupled to PPi generation is upregulated as cultured VSMC undergo contact-inhibition of proliferation or deposit extracellular matrix.


2017 ◽  
Vol 80 (7) ◽  
pp. 2018-2025 ◽  
Author(s):  
Nguyen Quoc Tuan ◽  
Do-Hyung Lee ◽  
Joonseok Oh ◽  
Chung Sub Kim ◽  
Kyung-Sun Heo ◽  
...  

2007 ◽  
Vol 43 (3) ◽  
pp. 301-307 ◽  
Author(s):  
Sven Wassmann ◽  
Kerstin Wassmann ◽  
Alexander Jung ◽  
Markus Velten ◽  
Pascal Knuefermann ◽  
...  

1995 ◽  
Vol 306 (3) ◽  
pp. 787-792 ◽  
Author(s):  
S M Yu ◽  
Z J Cheng ◽  
J H Guh ◽  
F Y Lee ◽  
S C Kuo

An indazole derivative, YC-1, was identified in this study to be capable of reversibly and effectively inhibiting proliferation of rat A10 vascular smooth-muscle cells (VSMCs) in vitro. YC-1 (1-100 microM) dose-dependently inhibited [3H]thymidine incorporation into DNA in rat A10 VSMCs that were synchronized by serum depletion and then restimulated by addition of 10% foetal calf serum (FCS), whereas FCS-induced [3H]thymidine incorporation into rat synchronized endothelial cells was unaffected by this agent. The dose of YC-1 required to cause inhibition of FCS-induced proliferation was similar to that necessary for the formation of cellular cyclic GMP (cGMP). Guanylate cyclase activity in soluble fractions of VSMCs was activated by YC-1 (1-100 microM), whereas cGMP-specific phosphodiesterase activity was unaffected by this compound. The anti-proliferative effect of YC-1 was mimicked by 8-bromo-cGMP, a membrane-permeable cGMP analogue, and was antagonized by KT 5823 (0.2 microM), a selective inhibitor of protein kinase G. The anti-proliferative effect of YC-1 was also antagonized by Methylene Blue (50 microM), a guanylate cyclase inhibitor, and was potentiated by 3-isobutyl-1-methylxanthine (500 microM), a phosphodiesterase inhibitor. These results verified that YC-1 is a direct soluble guanylate cyclase activator in A10 VSMCs, and the anti-proliferative effect of YC-1 is mediated by cGMP. YC-1 still inhibited FCS-induced DNA synthesis even when added 10-18 h after restimulation of the serum-deprived A10 VSMCs with 10% FCS. Flow cytometry in synchronized populations revealed an acute blockage of FCS-inducible cell-cycle progression at a point in the G1/S-phase in YC-1 (100 microM)-treated cells. The inhibition of proliferation by YC-1 was demonstrated to be independent of cell damage, as documented by several criteria of cell viability. In conclusion, YC-1 reversibly and effectively inhibited the proliferation of VSMCs, suggesting that it has potential as a therapeutic agent in the prevention of vascular diseases.


Sign in / Sign up

Export Citation Format

Share Document